Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells
- 1 March 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (6) , 469-476
- https://doi.org/10.1038/sj.gt.3301415
Abstract
Suicide gene therapy using viral transfer of herpes simplex virus type I (HSV-1) thymidine kinase (TK) and subsequent ganciclovir (GCV) chemotherapy was the first approach used in clinical trials of somatic gene therapy for glioblastoma. The molecular pathways mediating TK/GCV-induced cell death remain to be elucidated. Here, we report that adenoviral (Ad)-TK/GCV-induced death is p53-independent and does not involve altered CD95 or CD95L expression. Ectopic expression of the preferential caspase 8 inhibitor, crm-A, inhibits Ad-CD95L-induced cell death but has no effect on TK/GCV cytotoxicity. LN-18 glioma cells selected for resistance to death receptor-mediated cell death do not acquire cross-resistance to TK/GCV. TK/GCV triggers mitochondrial cytochrome c release and activation of caspases 3, 7, 8 and 9 in a death receptor-independent manner. These events are associated with the loss of BCL-XL. Forced expression of a BCL-XL transgene, or co-exposure to a pseudosubstrate caspase inhibitor, zVAD-fmk, inhibit TK/GCV cytotoxicity. Double-transfected cell lines expressing crm-A and enhanced green fluorescent protein (eGFP) show that the bystander effect in vitro is also death receptor- and caspase 8-independent. TK/GCV therapy does not kill glioma cells in synergy with cancer chemotherapy drugs, including lomustine, temozolomide and topotecan. In contrast, there is strong synergy of TK/GCV and CD95L. Thus, TK/GCV-induced cell death involves a mitochondria-dependent loop of caspase acvtivation that can be synergistically enhanced by death receptor agonists such as CD95L. TK/GCV-mediated sensitization of glioma cells to CD95L expressed on immune effector cells or parenchymal brain cells might account for the immune system's and bystander effects of TK/GCV therapy observed in rodent glioma models in vivo.Keywords
This publication has 22 references indexed in Scilit:
- Accumulation of Mutant p53V143A Modulates the Growth, Clonogenicity, and Radiochemosensitivity of Malignant Glioma Cells Independent of Endogenous p53 StatusExperimental Cell Research, 1999
- Synergy between the Herpes Simplex Virus tk/Ganciclovir Prodrug Suicide System and the Topoisomerase I Inhibitor TopotecanHuman Gene Therapy, 1999
- Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cellsOncogene, 1999
- Treatment of Experimental Glioma by Administration of Adenoviral Vectors Expressing Fas LigandHuman Gene Therapy, 1999
- Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinaseGene Therapy, 1999
- Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transferCancer Gene Therapy, 1999
- Increased Bax Expression Is Associated with Cell Death Induced by Ganciclovir in a Herpes Thymidine Kinase Gene-Expressing Glioma Cell LineHuman Gene Therapy, 1999
- Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent MannerThe Journal of cell biology, 1999
- Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processingCell Death & Differentiation, 1998
- Ganciclovir Chemoablation of Herpes Thymidine Kinase Suicide Gene-Modified Tumors Produces Tumor Necrosis and Induces Systemic Immune ResponsesHuman Gene Therapy, 1998